Category: Bio & Healthcare

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Samsung Biologics disclosed that its FY2025 consolidated revenue increased by 30.3% year-on-year to approximately KRW 4.56T and operating profit rose 56.6% to KRW 2.07T, driven by full operation of Plant 4 and stable operations at Plants 1-3. 📊 [Key Disclosure Details & Financial Figures] 📝 Editor’s…

Read More “[Disclosure] Samsung Biologics (207940) – Change in Revenue or Income Structure Exceeding 30% (15% for Large-Scale Corporations) / 2026-01-21” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Samsung Biologics disclosed its provisional Q4 2025 consolidated revenue of KRW 1.29T and operating profit of KRW 528.3B, bringing its full-year 2025 cumulative revenue to KRW 4.56T, up 30.3% year-on-year. 📊 [Key Disclosure Details & Financial Figures] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Comparing Preliminary…

Read More “[Disclosure] Samsung Biologics (207940) – Provisional Performance (Fair Disclosure) / 2026-01-21” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary ALTEOGEN entered into an exclusive licensing agreement with Tesaro, Inc., a subsidiary of GSK, for the development and commercialization of a subcutaneous (SC) formulation of GSK’s anticancer treatment dostarlimab using ALT-B4 technology. The deal is valued at up to USD 285M (approx. KRW 420B), including an…

Read More “[Disclosure] ALTEOGEN (196170) – Exclusive License Agreement for ALT-B4 / 2026-01-20” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary ALTEOGEN will participate in the ‘J.P. Morgan Healthcare Conference 2026’ in San Francisco, USA, to present its bio-platform technology and pipeline status/plans to major overseas institutional investors. 📊 [Key Disclosure Details & Major Figures Summary] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Verification of Bio-Platform Technology…

Read More “[Disclosure] ALTEOGEN (196170) – Investor Relations (IR) Host / 2026-01-08” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Samsung Biologics has announced that it plans to release its annual earnings results for FY2025 on January 21, 2026. 📊 [Key Disclosure Details & Financial Figures] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Verifying the Execution and Official Content of the Scheduled FY2025 Earnings Release on…

Read More “[Disclosure] Samsung Biologics (207940) – Advance Notice of Earnings Release (Information Disclosure) / 2026-01-07” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion’s US subsidiary (Celltrion USA, Inc.) has signed a pharmaceutical contract manufacturing agreement (CMO) worth approx. KRW 678.7B with Eli Lilly and Company. 📊 [Key Disclosure Details & Financial Summary] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Verification of Supply Commencement in Q2 2026 and Subsidiary…

Read More “[Disclosure] Celltrion (068270) – Other Major Management Matters (Voluntary Disclosure by Subsidiary) / 2026-01-02” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary ALTEOGEN announced a change of Chief Executive Officer (CEO), appointing Tae-Yeon Jun as the new CEO to replace the outgoing CEO Soon-Jae Park. 📊 [Key Disclosure Details & Major Figures Summary] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Verification of Governance Changes and Management Transition This…

Read More “[Disclosure] ALTEOGEN (196170) – Change of Chief Executive Officer / 2025-12-26” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Samsung Biologics has voluntarily disclosed that its 100% subsidiary, Samsung Biologics America, Inc., resolved to acquire 100% shares of US-based Human Genome Sciences Inc. from GSK for approximately KRW 413.6B to secure local drug substance manufacturing facilities. 📊 [Key Disclosure Details & Financial Figures] 📝 Editor’s…

Read More “[Disclosure] Samsung Biologics (207940) – Decision on Acquisition of Shares and Equity Securities of Other Corporations (Voluntary Disclosure) / 2025-12-22” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Samsung Biologics has voluntarily disclosed a pharmaceutical contract manufacturing agreement worth approximately KRW 56.7B with a pharmaceutical company based in Europe. 📊 [Key Disclosure Details & Financial Figures] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Tracking Revenue and Earnings Recognition Over Contract Period This disclosure was…

Read More “[Disclosure] Samsung Biologics (207940) – Single Sales and Supply Contract (Voluntary Disclosure) / 2025-12-22” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Samsung Biologics has voluntarily disclosed a pharmaceutical contract manufacturing agreement worth approximately KRW 56.1B with a pharmaceutical company based in Europe. 📊 [Key Disclosure Details & Financial Figures] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Tracking Revenue and Earnings Recognition Over Contract Period This disclosure was…

Read More “[Disclosure] Samsung Biologics (207940) – Single Sales and Supply Contract (Voluntary Disclosure) / 2025-12-22” »